| Literature DB >> 35945984 |
Sisi Zhang1, Houjuan Zuo1, Xiaoping Meng2, Dayi Hu1,3.
Abstract
Aim: To describe a new model, the Support Life Club (SLC), for participants of Phase II cardiac rehabilitation (CR) programs and to evaluate this model for adherence, completion rates, and clinical outcomes.Entities:
Keywords: WeChat platform; adherence; cardiac rehabilitation; completion rate; support life club
Year: 2022 PMID: 35945984 PMCID: PMC9357385 DOI: 10.2147/PPA.S368615
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.314
Baseline Characteristics of Patients in Participation and Non-Participation Groups
| Variables | Categories | SLC Group (200) N (%) | Control Group (193) N (%) | p | |
|---|---|---|---|---|---|
| Gender | Male | 142 (71.0%) | 135 (69.9%) | 0.052 | 0.819 |
| Female | 58 (29.0%) | 58 (30.1%) | |||
| Age (year) | Mean±SD | 59.89±9.30 | 63.51±9.99 | −3.723 | 0.000 |
| BMI (kg/m2) | Mean±SD | 26.07±3.11 | 27.02±2.42 | −3.414 | 0.001 |
| CAD | Yes | 176 (88.0%) | 189 (97.9%) | 14.629 | 0.000 |
| No | 24 (12.0%) | 4 (2.1%) | |||
| HF | Yes | 22 (11.0%) | 27 (14.0%) | 0.804 | 0.370 |
| No | 178 (89.0%) | 166 (86.0%) | |||
| AF | Yes | 29 (14.5%) | 27 (14.0%) | 0.021 | 0.885 |
| No | 171 (85.5%) | 166 (86.0%) | |||
| CABG | Yes | 7 (3.5%) | 19 (9.8%) | 6.399 | 0.011 |
| No | 193 (96.5%) | 174 (90.2%) | |||
| PCI | Yes | 82 (41.0%) | 56 (29.0%) | 6.192 | 0.013 |
| No | 118 (59.0%) | 137 (71.0%) | |||
| Hypertension | Yes | 76 (38.0%) | 114 (59.1%) | 17.456 | 0.000 |
| No | 124 (62.0%) | 79 (40.9%) | |||
| Diabetes | Yes | 55 (27.5%) | 60 (31.1%) | 0.611 | 0.434 |
| No | 145 (72.5%) | 133 (68.9%) | |||
| Platelet inhibitors | Yes | 192 (96.0%) | 193 (100.0%) | 6.002 | 0.014 |
| No | 8 (4.0%) | 0 (0.0%) | |||
| β-block | Yes | 153 (76.5%) | 94 (48.7%) | 32.499 | 0.000 |
| No | 47 (23.5%) | 99 (51.3%) | |||
| Statins | Yes | 173 (86.5%) | 148 (76.7%) | 5.685 | 0.017 |
| No | 27 (13.5%) | 45 (23.3%) | |||
| ACEI/ARB | Yes | 96 (48.0%) | 193 (100.0%) | 136.476 | 0.000 |
| No | 104 (52.0%) | 0 (0.0%) | |||
| CCB | Yes | 59 (29.5%) | 192 (99.5%) | 208.444 | 0.000 |
| No | 141 (70.5%) | 1 (0.5%) | |||
| Anti-anxiety/dipression | Yes | 21 (10.5%) | 20 (10.4%) | 0.002 | 0.964 |
| No | 179 (89.5%) | 173 (89.6%) | |||
| Systolic BP (mmHg) | Mean±SD | 126.65±14.07 | 136.34±22.17 | −5.104 | 0.000 |
| Diastolic BP (mmHg) | Mean±SD | 76.21±10.19 | 78.08±8.54 | −1.969 | 0.0497 |
| TC (mmol/L) | Mean±SD | 3.36±0.91 | 2.93±0.71 | 5.283 | 0.000 |
| TG (mmol/L) | Mean±SD | 2.01±0.91 | 2.19±0.90 | −1.954 | 0.051 |
| HDL-C (mmol/L) | Mean±SD | 1.99±0.78 | 2.12±0.53 | −1.812 | 0.071 |
| LDL-C (mmol/L) | Mean±SD | 1.13±0.50 | 1.03±0.39 | 2.280 | 0.023 |
| Hg (g/L) | Mean±SD | 125.86±8.20 | 121.87±9.18 | 4.534 | 0.000 |
Abbreviations: BMI, Body Mass Index; CAD, coronary artery disease; HF, heart failure; AF, atrial fibrillation; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; ACEI, Angiote nsin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blocker; BP, blood pressure; TC, total cholesterol; TG, triacylglycerol; HDL-C, High density Lipoprotein cholesterol; LDL-C, Low Density Lipoprotein cholesterol.
Adherence and Completion Rate Between Groups
| Variable | Categories | SLC Group (200) N (%) | Control Group (193) N (%) | p | |
|---|---|---|---|---|---|
| Adherence | More than 75% of sessions | 145 (72.5%) | 78 (40.41%) | 41.195 | 0.000 |
| Less than 75% of sessions | 55 (27.5%) | 115 (59.59%) | |||
| Completion rates | Percent (%) | 80.4% | 56.6% | 12.084 | 0.000 |
Within-Group Change and Comparison of Between-Group Differences for the Two Groups
| Variables | Groups | Pre (Mean±SD) | Post (Mean±SD) | Mean Within-Group Differences | Mean Between-Group Differences | Significance (F, p, Effect Size) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Time | Group× Time | ||||||||||||
| PHQ-9 | SLC group | 5.16±5.53 | 2.32±2.87 | −2.84±3.68* | 1.82±0.3* | 24.09 | 0.000 | 0.049 | 168.03 | 0.000 | 0.067 | 37.62 | 0.000 | 0.016 |
| Control group | 2.61±2.98 | 1.59±2.06 | −1.02±1.91* | |||||||||||
| 6MWT | SLC group | 650.48±74.70 | 693.69±81.78 | 43.21±60.25 | 36.32±5.06 | 514.032 | 0.000 | 0.545 | 98.456 | 0.000 | 0.025 | 51.438 | 0.000 | 0.013 |
| Control group | 495.61±72.76 | 502.57±86.73 | 6.96±36.59* | |||||||||||
| peakVO2 | SLC group | 13.8±4.65 | 15±4.26 | 1.8±3.5* | 0.18±0.3 | 3.946 | 0.048 | 0.009 | 54.754 | 0.000 | 0.013 | 0.389 | 0.533 | 0.000 |
| Control group | 13±4.82 | 14±5.38 | 1±2.2* | |||||||||||
| AT | SLC group | 11.1±3.93 | 12.24±3.67 | 1.14±3.53* | −0.27±0.29 | 21.708 | 0.000 | 0.046 | 74.323 | 0.000 | 0.025 | 0.836 | 0.361 | 0.000 |
| Control group | 12.7±4.03 | 14.11±4.24 | 1.4±2.11* | |||||||||||
Note: *p<0.001.